PL2854849T3 - Stabilizowane formulacje zawierające przeciwciała anty-dll4 - Google Patents

Stabilizowane formulacje zawierające przeciwciała anty-dll4

Info

Publication number
PL2854849T3
PL2854849T3 PL13730702T PL13730702T PL2854849T3 PL 2854849 T3 PL2854849 T3 PL 2854849T3 PL 13730702 T PL13730702 T PL 13730702T PL 13730702 T PL13730702 T PL 13730702T PL 2854849 T3 PL2854849 T3 PL 2854849T3
Authority
PL
Poland
Prior art keywords
formulations containing
containing anti
dll4 antibodies
stabilized formulations
stabilized
Prior art date
Application number
PL13730702T
Other languages
English (en)
Inventor
Scott Walsh
Daniel Dix
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48670784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2854849(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of PL2854849T3 publication Critical patent/PL2854849T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
PL13730702T 2012-05-31 2013-05-31 Stabilizowane formulacje zawierające przeciwciała anty-dll4 PL2854849T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261653478P 2012-05-31 2012-05-31
PCT/US2013/043516 WO2013181486A1 (en) 2012-05-31 2013-05-31 Stabilized formulations containing anti-dll4 antibodies
EP13730702.1A EP2854849B1 (en) 2012-05-31 2013-05-31 Stabilized formulations containing anti-dll4 antibodies

Publications (1)

Publication Number Publication Date
PL2854849T3 true PL2854849T3 (pl) 2018-07-31

Family

ID=48670784

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13730702T PL2854849T3 (pl) 2012-05-31 2013-05-31 Stabilizowane formulacje zawierające przeciwciała anty-dll4

Country Status (30)

Country Link
US (1) US9675692B2 (pl)
EP (1) EP2854849B1 (pl)
JP (1) JP6144758B2 (pl)
KR (1) KR20150033615A (pl)
CN (1) CN104349791A (pl)
AR (1) AR092325A1 (pl)
AU (1) AU2013267301B2 (pl)
BR (1) BR112014028997A2 (pl)
CA (1) CA2872275C (pl)
CL (1) CL2014003237A1 (pl)
CO (1) CO7151478A2 (pl)
DK (1) DK2854849T3 (pl)
EA (1) EA029779B1 (pl)
ES (1) ES2668900T3 (pl)
HK (1) HK1207305A1 (pl)
IL (1) IL235468A0 (pl)
LT (1) LT2854849T (pl)
MA (1) MA37645B1 (pl)
MX (1) MX357146B (pl)
NO (1) NO2887943T3 (pl)
NZ (1) NZ702288A (pl)
PH (1) PH12014502429B1 (pl)
PL (1) PL2854849T3 (pl)
PT (1) PT2854849T (pl)
SG (1) SG11201407171XA (pl)
SI (1) SI2854849T1 (pl)
SM (1) SMT201800216T1 (pl)
TW (1) TWI609696B (pl)
UY (1) UY34842A (pl)
WO (1) WO2013181486A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883145B2 (en) 2009-10-16 2014-11-11 Oncomed Pharmaceuticals, Inc. Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
SI3485903T1 (sl) 2011-09-23 2023-02-28 Mereo Biopharma 5, Inc. Sredstva, ki vežejo VEGF/DLL4, in njihove uporabe
US20160176962A1 (en) 2014-10-31 2016-06-23 Oncomed Pharmaceuticals, Inc. Combination Therapy For Treatment Of Disease
EP3207936B1 (en) * 2014-11-18 2021-04-21 Shionogi & Co., Ltd. Stable peptide composition
ES2968074T3 (es) 2015-09-23 2024-05-07 Mereo Biopharma 5 Inc Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino
AU2019254473A1 (en) * 2018-04-16 2020-12-03 Merck Patent Gmbh Additives for protein formulations to improve thermal stability
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
KR20230035595A (ko) * 2020-07-08 2023-03-14 리제너론 파아마슈티컬스, 인크. 항-ctla-4 항체를 함유하는 안정화된 제형

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
US5016784A (en) 1990-02-15 1991-05-21 Dexus Research Inc. Applicator for highly reactive materials
WO1993000807A1 (en) 1991-07-03 1993-01-21 Cryolife, Inc. Method for stabilization of biomaterials
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
EP0999853B1 (en) 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US7001892B1 (en) 1999-06-11 2006-02-21 Purdue Research Foundation Pharmaceutical materials and methods for their preparation and use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
JP5485489B2 (ja) 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
JP4340062B2 (ja) 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
AU2002324556A1 (en) 2001-07-25 2003-02-17 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
EP3192528A1 (en) 2002-02-14 2017-07-19 Chugai Seiyaku Kabushiki Kaisha Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
AU2004229335C1 (en) 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
WO2005072772A1 (en) 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
HUE034109T2 (en) 2005-03-25 2018-01-29 Regeneron Pharma VEGF antagonist formulations
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
SI2944306T1 (sl) 2006-06-16 2021-04-30 Regeneron Pharmaceuticals, Inc. Formulacije antagonista VEGF, primerne za intravitrealno dajanje
US20100129354A1 (en) 2006-10-27 2010-05-27 Ablynx N.V. Intranasal delivery of polypeptides and proteins
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
BRPI1006519A2 (pt) 2009-03-06 2016-08-09 Genentech Inc formulação de anticorpos
US8883145B2 (en) * 2009-10-16 2014-11-11 Oncomed Pharmaceuticals, Inc. Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
BR112012012080B1 (pt) 2009-11-20 2022-11-29 Biocon Limited Formulações de histidina-trealose do anticorpo t1h
EP2542582A4 (en) 2010-03-02 2013-12-04 Abbvie Inc THERAPEUTIC PROTEINS LINKING TO DLL4
CN106267189B (zh) * 2010-10-06 2021-02-26 瑞泽恩制药公司 含有抗白介素-4受体(il-4r)的抗体的稳定制剂

Also Published As

Publication number Publication date
NZ702288A (en) 2016-12-23
CL2014003237A1 (es) 2015-07-10
US9675692B2 (en) 2017-06-13
MA37645A3 (fr) 2017-07-31
EA029779B1 (ru) 2018-05-31
CO7151478A2 (es) 2014-12-29
CA2872275A1 (en) 2013-12-05
SI2854849T1 (en) 2018-05-31
PH12014502429A1 (en) 2015-01-12
DK2854849T3 (en) 2018-04-30
UY34842A (es) 2013-12-31
MX357146B (es) 2018-06-28
MX2014014363A (es) 2015-02-05
SG11201407171XA (en) 2014-11-27
MA37645A2 (fr) 2016-08-31
US20130323260A1 (en) 2013-12-05
WO2013181486A1 (en) 2013-12-05
EP2854849B1 (en) 2018-02-28
CN104349791A (zh) 2015-02-11
MA37645B1 (fr) 2018-10-31
CA2872275C (en) 2021-05-18
AU2013267301A1 (en) 2014-12-18
LT2854849T (lt) 2018-05-10
SMT201800216T1 (it) 2018-05-02
JP6144758B2 (ja) 2017-06-07
TW201400130A (zh) 2014-01-01
EP2854849A1 (en) 2015-04-08
PT2854849T (pt) 2018-05-09
NO2887943T3 (pl) 2018-05-05
ES2668900T3 (es) 2018-05-23
EA201492186A1 (ru) 2015-08-31
PH12014502429B1 (en) 2015-01-12
KR20150033615A (ko) 2015-04-01
BR112014028997A2 (pt) 2017-07-25
HK1207305A1 (en) 2016-01-29
JP2015520173A (ja) 2015-07-16
IL235468A0 (en) 2014-12-31
TWI609696B (zh) 2018-01-01
AU2013267301B2 (en) 2018-02-08
AR092325A1 (es) 2015-04-15

Similar Documents

Publication Publication Date Title
IL276234B (en) Antibody compositions
IL233482A0 (en) Stabilized formulations that include anti-ang2 antibodies
IL265501A (en) Stabilized liquid formulations containing antibody
PL3117837T3 (pl) Formulacje przeciwciała
IL235966A0 (en) Antibody formulation
SMT202000427T1 (it) Formulazioni stabili contenenti anticorpi anti-pcsk9 domande correlate
IL235807A0 (en) Immunoprecipitates containing anti–cd79b antibodies
IL235989A0 (en) Immunoprecipitates containing anti–cd79b antibodies
IL230282B (en) Stable formulations containing anti-9pcsk antibody field
AP2014008102A0 (en) Anti-FcRn antibodies
EP2841082A4 (en) ANTIBODIES REGULATED BY PROTEASES
PL3181122T3 (pl) Kompozycja farmaceutyczna dazatynibu
ZA201504564B (en) Anti her2 antibody formulation
SG11201407171XA (en) Stabilized formulations containing anti-dll4 antibodies
EP2729164A4 (en) FORMULATIONS STABILIZING PROTEINS
PL2851083T3 (pl) Kompozycja białkowa odporna na sterylizację promieniowaniem
ZA201404909B (en) Stabilized formulations containing anti-ang2 antibodies